Testing a new combination treatment for brain lymphoma

Plain-English translation of NCT07410520 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new treatment combination called PD-1i+RMO for people with a rare type of lymphoma (cancer) that develops in or spreads to the brain. The combination includes a PD-1 inhibitor, rituximab, , and . The goal is to see if this medication combination can help more patients achieve a complete remission and live longer than current standard treatments.

Brain lymphoma is difficult to treat and currently has a poor outlook, with most patients surviving only 1–2 years. This trial exists because researchers believe that adding newer targeted medications to the standard chemotherapy could improve survival and help patients stay in remission longer.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with primary CNS lymphoma (lymphoma that started in the brain or spinal cord) confirmed by a biopsy, or you have relapsed secondary CNS lymphoma that has spread to the brain
you have had a brain MRI scan within the past 28 days showing at least one measurable tumor
your organs (heart, liver, kidneys) and bone marrow are functioning well enough to tolerate strong medications, based on blood tests
you are age 18 or older with a life expectancy of at least 3 months
you are willing to use effective contraception for the entire treatment period plus 90 days after your last dose if you can have children

You likely don't qualify if…

you have lymphoma outside the brain or nervous system
you have a history of a different cancer within the past 5 years (except skin cancer or early cervical cancer that was successfully treated)
you have a known severe allergy to any component of the treatment medications
you have previously received other immunotherapy drugs (anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies, or CAR-T cell therapy)
you have had an organ transplant or bone marrow transplant in the past

What participation looks like

You would come to the hospital for treatment visits every 3 weeks for 8 cycles (about 6 months total). At each visit, you would receive the four-drug combination as an infusion or injection. After 4 cycles, you would have imaging scans (MRI and CT or PET scan) to check how well the treatment is working. If your lymphoma is responding, you would continue for 4 more cycles, followed by repeat scans. Throughout the trial, you would have regular blood tests to monitor your health and watch for side effects.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

China

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu